Fas (APO-1, CD95) receptor expression and new options for immunotherapy in childhood medulloblastomas

被引:0
|
作者
Bodey, B
Bodey, B
Siegel, SE
Kaiser, HE
机构
[1] Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA
[2] Childrens Hosp Los Angeles, Childrens Ctr Canc & Blood Dis, Los Angeles, CA 90027 USA
[3] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[4] Univ Vienna, Dept Gen & Expt Pathol, Vienna, Austria
关键词
primitive neuroectodermal tumor (PNET); childhood medulloblastoma (MED); apoptosis or programmed cell death (PCD) or active cell death (ACD); calcium and magnesium dependent endonucleases; fas (APO-1 or CD95) receptor (FasR); condensation of cellular chromatin; DNA fragmentation; apoptotic bodies; immunocytochemistry; antibodies; Fas ligand (FasL); bcl; 2; bax;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Central nervous system (CNS) tumors are the most common solid neoplasms in children. Medulloblastomas (MEDs) resemble embryonic neuroectodermal stem cells and their immature, uncommitted neuronal and glial progeny. Apoptosis is a basic physiological process wherein the cell initiates a sequence of events culminating in the fragmentation of its DNA, nuclear collapse, and finally, disintegration of the cell into small, membrane-bound apoptotic bodies. Expression of Fas (APO-1, CD95) receptor (FasR) and programmed ol active cell death (PCD) was studied in childhood MEDs with varying stages of malignancy, and cell differentiation features. The majority of neoplastically transformed neuroectodermal in origin cells, particularly in MEDs, express FasR, whereas normal cells in the CNS do not. FasR is a transmembrane glycoprotein, which belongs to the nerve growth factor/tumor necrosis factor (NGF/TNF) receptor superfamily. Apoptosis within childhood PNETs/MEDs is triggered by the binding of FasR to ifs natural ligand (FasL) or. by cross-linking with anti- i FasR antibodies. The resence of FasL has also been detected in childhood glial tumors. Therefore, a spontaneous, cellular immunophenotype (IP) regulatory, intratumoral apoptotic cell death (autocrine suicide) is possible in childhood brain tumors during neoplastic growth and progression. During our systematic immunocytochemical screening, we employed formalin fixed, paraffin-wax embedded tissue sections, as well as frozen sections of 34 primary human childhood PNETs/MEDs. The use of a sensitive, indirect, six step immunoperoxidase or alkaline phosphatase conjugated streptavidin-biotin antigen detection technique, modified by us, provided excellent immunocytochemical results. A systematic observation of the presence of apoptosis related markers (especially FasR) and cells in PCD was carried out. A strong expression (intensity of staining: "A"-the highest possible; number of stained neoplastic cells: +++ to ++++, between 50% to 90%) of FasR, was detected employing 4 mu m thick, formalin fixed, paraffin-wax embedded tissue slides. The panel of normal tissues employed as positive and negative tissue controls demonstrated presence of FasR in the prenatal thymus, mature tonsils and colon epithelium. Certainly, the coexpression of FasR, FasL, and other PCD-related proteins have also been reported in other human malignancies: breast cancel; colorectal carcinomas, large granular lymphocytic leukemia of T or NK cell origin melanomas, lung, prostate, pancreas, and hepatocellular carcinomas. The coexpression of both FasR and FasL on several neoplastic cell types may represent an effective mechanism for tumor escape of the cellular immunological response of the host. It has been well established that brain tumors and melanomas produce their autocrine FasL, and even become capable of switching their signal transduction from the PCD pathway to a tumor growth, proliferative pathway. It seems that the therapeutical use of FasR-FasL (main apoptotic pathway) represents a new and exciting immunotherapeutical possibility in the treatment of primary childhood neuroectodermal tumors.
引用
收藏
页码:3293 / 3314
页数:22
相关论文
共 50 条
  • [1] Fas/APO-1 (CD95) expression in myelodysplastic syndromes
    Lepelley, P
    Grardel, N
    Erny, O
    Iaru, T
    Obein, V
    Cosson, A
    Fenaux, P
    LEUKEMIA & LYMPHOMA, 1998, 30 (3-4) : 307 - 312
  • [2] Fas antigen/APO-1 (CD95) expression on myeloma cells
    Shima, Y
    Nishimoto, N
    Yoshizaki, K
    Kishimoto, T
    LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 521 - +
  • [3] The CD95(APO-1/Fas) DISC and beyond
    M E Peter
    P H Krammer
    Cell Death & Differentiation, 2003, 10 : 26 - 35
  • [4] CD95(apo-1/fas) signalling and diseases
    Krammer, PH
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2003, 367 : R1 - R1
  • [5] The CD95(APO-1/Fas) DISC and beyond
    Peter, ME
    Krammer, PH
    CELL DEATH AND DIFFERENTIATION, 2003, 10 (01): : 26 - 35
  • [6] Fas (CD95/Apo-1) expression and apoptosis in myelodysplasia.
    Bouscary, D
    DeVos, J
    FontenayRoupie, M
    Melle, J
    Jondeau, K
    Picard, F
    Dreyfus, F
    Guesnu, M
    BLOOD, 1996, 88 (10) : 2544 - 2544
  • [7] Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma
    Gross, N
    Balmas, K
    Brognara, CB
    Tschopp, J
    MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 36 (01): : 111 - 114
  • [8] The CD95(APO-1/Fas)/CD95L system
    Krammer, PH
    TOXICOLOGY LETTERS, 1998, 103 : 131 - 137
  • [9] Control of neuronal branching by the death receptor CD95 (Fas/Apo-1)
    C Zuliani
    S Kleber
    S Klussmann
    T Wenger
    M Kenzelmann
    N Schreglmann
    A Martinez
    J A del Rio
    E Soriano
    P Vodrazka
    R Kuner
    H-J Groene
    I Herr
    P H Krammer
    A Martin-Villalba
    Cell Death & Differentiation, 2006, 13 : 31 - 40
  • [10] Characterization of Fas (Apo-1, CD95)-Fas ligand interaction
    Schneider, P
    Bodmer, JL
    Holler, N
    Mattmann, C
    Scuderi, P
    Terskikh, A
    Peitsch, MC
    Tschopp, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (30) : 18827 - 18833